GPCR Valuation

Structure Therapeutics Inc

Add to Watchlist

Advanced Chart

18.300

+0.36(2.007%)1D

Overview
Forecast
Valuation
Earnings

GPCR Relative Valuation

GPCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GPCR is overvalued; if below, it's undervalued.

Historical Valuation

Structure Therapeutics Inc (GPCR) is now in the Fair zone, suggesting that its current forward PS ratio of 21.02 is considered Fairly compared with the five-year average of -36.81. The fair price of Structure Therapeutics Inc (GPCR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：18.61

Fair

-14.77

Trailing

Forward

-0.92

EV/EBITDA

Structure Therapeutics Inc. (GPCR) has a current EV/EBITDA of -0.92. The 5-year average EV/EBITDA is -3.99. The thresholds are as follows: Strongly Undervalued below -12.48, Undervalued between -12.48 and -8.24, Fairly Valued between 0.25 and -8.24, Overvalued between 0.25 and 4.50, and Strongly Overvalued above 4.50. The current Forward EV/EBITDA of -0.92 falls within the Historic Trend Line -Fairly Valued range.

-0.89

EV/EBIT

Structure Therapeutics Inc. (GPCR) has a current EV/EBIT of -0.89. The 5-year average EV/EBIT is -8.02. The thresholds are as follows: Strongly Undervalued below -17.10, Undervalued between -17.10 and -12.56, Fairly Valued between -3.48 and -12.56, Overvalued between -3.48 and 1.06, and Strongly Overvalued above 1.06. The current Forward EV/EBIT of -0.89 falls within the Overvalued range.

21.02

Structure Therapeutics Inc. (GPCR) has a current PS of 21.02. The 5-year average PS is 4.15. The thresholds are as follows: Strongly Undervalued below -14.84, Undervalued between -14.84 and -5.35, Fairly Valued between 13.64 and -5.35, Overvalued between 13.64 and 23.14, and Strongly Overvalued above 23.14. The current Forward PS of 21.02 falls within the Overvalued range.

-8.02

P/OCF

Structure Therapeutics Inc. (GPCR) has a current P/OCF of -8.02. The 5-year average P/OCF is -13.38. The thresholds are as follows: Strongly Undervalued below -21.91, Undervalued between -21.91 and -17.64, Fairly Valued between -9.11 and -17.64, Overvalued between -9.11 and -4.84, and Strongly Overvalued above -4.84. The current Forward P/OCF of -8.02 falls within the Overvalued range.

-4.36

P/FCF

Structure Therapeutics Inc. (GPCR) has a current P/FCF of -4.36. The 5-year average P/FCF is -11.21. The thresholds are as follows: Strongly Undervalued below -23.38, Undervalued between -23.38 and -17.29, Fairly Valued between -5.12 and -17.29, Overvalued between -5.12 and 0.97, and Strongly Overvalued above 0.97. The current Forward P/FCF of -4.36 falls within the Overvalued range.

Structure Therapeutics Inc (GPCR) has a current Price-to-Book (P/B) ratio of 1.25. Compared to its 3-year average P/B ratio of 3.88 , the current P/B ratio is approximately -67.75% higher. Relative to its 5-year average P/B ratio of 3.88, the current P/B ratio is about -67.75% higher. Structure Therapeutics Inc (GPCR) has a Forward Free Cash Flow (FCF) yield of approximately -12.96%. Compared to its 3-year average FCF yield of -5.81%, the current FCF yield is approximately 122.90% lower. Relative to its 5-year average FCF yield of -5.81% , the current FCF yield is about 122.90% lower.

1.25

P/B

Median3y

3.88

Median5y

3.88

-12.96

FCF Yield

Median3y

-5.81

Median5y

-5.81

Competitors Valuation Multiple

The average P/S ratio for GPCR's competitors is 4.65, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR) exhibits a P/S ratio of 21.02, which is 352.21% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GPCR.O

Structure Therapeutics Inc

Collegium Pharmaceutical Inc

Pacira Biosciences Inc

Amphastar Pharmaceuticals Inc

1.46

-0.76%

1.05B

Performance Decomposition

Market capitalization of GPCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GPCR in the past 1 year is driven by Unknown.